Cabenuva Outperforms Biktarvy in PhIII Trial with 90% Patient Preference
In a Phase III trial comparing ViiV Healthcare's long-acting injectable Cabenuva with Gilead Sciences' daily pill Biktarvy for HIV treatment, the majority of patients preferred the injection over the pill, citing various physical and emotional benefits. Patients also reported improved adherence to the medication and emotional and psychological benefits. The study found that Cabenuva was "non-inferior" to Biktarvy in terms of efficacy and was preferred by 90% of patients after 12 months of treatment.